Topic Listing for Amgen

Abgenix Inc Acquisition Acceleration
Accomplishments Accordance 306 Sarbanes-oxley Act 2002 Rule 104 Regulation
Accounting Method Convertible Debt Securities Subject Change Accounting Standards
Accounts Trust Funding Accrued Liabilities
Accumulated Other Comprehensive Income Acknowledgement Guarantor
Acknowledgements Acquired In-process Research Development
Acquisition Acquisitions
Act Acts Holders
Actual Share Purchase Amount Actual Share Purchase Value
Additional Agreements Representations Covenants Counterparty Etc Additional Borrowers Termination
Additional Notice Requirements Additional Termination Events
Additional Terms Awards Address Notices Communications Bank Purposes
Address Notices Communications Counterparty Purposes Address Notices Communications Msil Purposes
Address Notices Communications Seller Purposes Adjusted Earnings Per Share Growth
Adjustment Cash Dividends Adjustment Change Capital Stock
Adjustment Conversion Rate After Public Acquirer Change Adjustment Deferred
Adjustment Other Distributions Adjustment Provisions
Adjustment Required Adjustment Rights Issue
Adjustment Tender Offer Administration
Administration Operation Plan Adopt Simple Majority Vote
Adopts Majority Vote Bylaw Advances General
Advantage Adopting Proposal Also Considered Context Overall Corporate Affected Parties
Aggregate Actual Share Purchase Value Aggregate Purchase Price Adjustment Value
Aggregated Option Exercises Agreement
Alantos Pharmaceutical Holding Inc Alantos Pharmaceuticals Holding Inc
Although Bi-partisan Campaign Reform Act 2002 Prohibits Corporate Amended Restated 1997 Equity Incentive Plan
Amended Restated 1997 Special Non-officer Equity Incentive Plan Amended Restated 1999 Equity Incentive Plan
Amended Restated 1999 Incentive Stock Plan Amended Restated Effective 2005
Amended Restated Effective 2006 Amended Restated Form Performance Unit Agreement
Amended Restated Forms Stock Option Grant Agreements Amended Restated Forms Stock Option Grant Agreements Restricted
Amended Restated Rights Agreement Amendment
Amendment Credit Agreement Amendment Deferred Compensation Plan
Amendment Definition Reference Market-makers Amendment Espp
Amendment Event Amendment Plan
Amendment Promissory Amendment Restatement Plans Corresponding Performance Program
Amendment Restatement Retirement Savings Plan Amendment Retirement Savings Plan
Amendment Supplemental Retirement Plan Amendment Termination
Amendment Termination Plan Amendments
Amendments Articles Incorporation Bylaws Change Amendments Credit Agreement
Amendments Restatement Certain Equity Plans Performance Program Related Amendments Restatement Director Equity Incentive Program Related Award
Amg 102 Amg 108
Amg 222 Amg 223
Amg 317 Amg 386
Amg 479 Amg 531
Amg 655 Amg 706
Amg 785 Amg 827
Amg 853 Amgen
Amgen Affirms Low End Eps Guidance Range Amgen Daiichi Sankyo Announce Agreement Denosumab Japan
Amgen Inc Amgen Inc Amended Restated
Amgen Inc Amended Restated 1997 Equity Incentive Plan Amgen Inc Amended Restated 1999 Stock Incentive Plan
Amgen Inc Ariad Pharmaceuticals Amgen Inc Executive Compensation
Amgen Inc Hoffmann-la Roche Ltd Amgen Inc International Business Machines Corporation
Amgen Inc Supplemental Retirement Plan Amgen Limited 2000 Employee Share Option Plan
Amgen Limited Sharesave Plan Amgen Nonqualified Deferred Compensation Plan
Amgen Offer Convertible Senior Notes Purchase Approximately Common Amgen Offer Series Senior Notes Purchase Approximately Common
Amgen Policy Procedures Majority Vote Standard Amgen Prices Convertible Senior Notes Purchase Approximately Common
Amgen Retirement Savings Plan Amgen Takeda Announce Exclusive Collaboration Japan Clinical Candidates
Amgen Technology Ireland Irish Tax Approved Share Plan Amortization Acquired Intangible Assets
Amortization Certain Acquired Intangible Assets Annual Cash Incentives
Annual Meeting Stockholders Annual Report Form 10-k
Anti-dilution Adjustments Appendix
Applicable Adjustment Rate Applicable Employer Affiliate Exclusive Purpose Implementing Administering Managing
Approval Amendment Restated Certificate Incorporation Eliminate Supermajority Voting Approval Proposed 2009 Equity Incentive Plan
Approved Awards Approved External
Approximately 2045 Companies Globally Produced Reports Sustainability Approximately Common Stock
Aranesp Aranesp Darbepoetin Alfa
Arbitration Demand Separate Bla Assignment Form
Attendance Annual Meeting Audit Committee
Audit Committee Board Directors Audit Committee Report
Audits Records Retention Australia
Austria Automatic Early Termination
Available Available-for-sale Securities
Average Wholesale Price Awp Litigation Average Wholesale Price Litigation
Avidia Inc Award Determinations
Award Restricted Stock Award Stock Appreciation Rights
Ayment B-18 Amount
Base Salaries Basic Representations
Basis Presentation Before Commercialize Sell Product Candidates Conduct Clinical Trials
Before Commercialize Sell Product Candidates Existing Products New Belgium
Beneficial Ownership Reporting Compliance Beneficiary Designation
Birch Sharer Blackout Period Amgen Retirement Savings Plan
Board Board Committees
Board Directors Board Directors Corporate Governance Highlights
Board Directors Recommends Vote Board Directors Recommends Vote Against Stockholder Proposal
Board Directors Recommends Vote Against Stockholder Proposal Following Board Directors Recommends Vote Approval Amendments Described Above
Board Directors Recommends Vote Each Nominee Named Above Board Directors Recommends Vote Ratification Selection Ernst Young
Board Directors Recommends Vote Stockholder Proposal Following Reasons Board Directors Stockholders Amgen Inc
Board Independence Board Independence Meetings Committees
Board Meetings Board Recommendations
Board Recommends Stockholders Vote Each Nominees Named Below Boehringer Ingelheim Pharma Gmbh
Bone Book-entry Provisions 201 Shall Apply Only Global Securities
Bradways Offer Letter Break Expense
Breast Cancer Broker Bank Other Nominee Was Record Holder Shares
Broker Bank Trust Other Nominee Was Record Holder Build Framework Future Growth Fail Execute Initiatives Business
Bulk Commercial Manufacturing Business
Business Affected Government Investigations Litigation Business Affected Litigation Government Investigations
Business Editors Business Impacted Government Investigations Litigation
Business Relationships Ca-amgen Amgn Amgens 2004 Adjusted Earnings Per Share
Calculation Agent Calculations
Canada Cancellation
Cash Compensation Cash Equivalents
Cash Equivalents Marketable Securities Cash Flows
Cautionary Statement Regarding Forward-looking Statements Ceo Compensation
Ceo Compensation Compared Other Named Executive Officers Certain Definitions
Certain Esa Postmarketing Commitments Certain Raw Materials Medical Devices Components Single-sourced Parties
Certain Relationships Related Transactions Certificate Designations
Certificate Opinion Conditions Precedent Certification Chief Executive Officer
Certification Chief Financial Officer Certifications
Change Control Change Control Benefits
Change Control Severance Plan Change Method Accounting Convertible Debt Instruments
Change-in-control Arrangements Changes Procedures Recommending Director Nominees
Changing Vote Charge Imposed Relation Thereto Other Expenses Including Fees
Chief Accounting Officer Chief Executive Officer Compensation Compared Other Named Officers
Claims Procedures Claims Review Procedures
Clinical Developments Clinical Manufacturing
Closing Price Code Ethics
Code Ethics Business Conduct Collaboration Agreement
Collaborative Arrangements Collect Receive Moneys Other Property Payable Deliverable Such
Collection Suit Trustee Commercial Bulk Manufacturing
Commercial Formulation Fill Finish Commercial Formulation Fill Finish Manufacturing
Commitments Commitments Contingencies
Common Stock Common Stock 00001 Par Value
Common Stock 00001 Par Value Preferred Share Purchase Common Stock Contractual Contingent Payment Rights
Commonwealth Kentucky Alphapharma Inc Commonwealth Kentucky Alpharma Inc
Commonwealth Pennsylvania Tap Pharmaceutical Products Inc Communication Board
Communication Holders Other Compensation Committee
Compensation Committee Board Directors Compensation Committee Consultant
Compensation Committee Consultants Compensation Committee Deliberations
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Discussion Analysis Compensation Executive Officers
Compensation Governance Best Practices Compensation Indemnity
Compensation Management Development Committee Compensation Program Structure-grade Levels
Competition Competitive Developments
Compliance Certificate Compliance Laws Policies
Compliance Trust Indenture Act Composition Total Direct Compensation
Comprehensive Income Conatumumab Amg 655
Concentration Sales Certain Wholesaler Distributors Consolidation Free-standing Dialysis Concentration Sales Certain Wholesaler Distributors Consolidation Freestanding Dialysis
Conditions Conditions Closing
Conditions Effectiveness Conduct Clinical Trials Humans Before Commercialize Sell Product
Confidential Confirmation
Confirmation Otc Convertible Hedge Confirmation Otc Warrant Transaction
Connecticut Retirement Plans Trust Funds Amgen Inc Consent Ernst Young Llp Independent Registered Public Accounting
Consent Holders Consent Independent Registered Public Accounting Firm
Consent Recording Consolidated System Time Such Purchases Effected Those Terms
Contingencies Continual Manufacturing Process Improvement Efforts Result Carrying Value
Continual Process Improvement Efforts Result Carrying Value Certain Continue Build Framework Future Growth Fail Execute Initiatives
Continuing Invest Innovation Future Growth Contractual Contingent Payment Rights
Contractual Maturities Long-term Debt Obligations Contractual Obligations
Contributions Control Majority
Controls Procedures Conversion Notice
Conversion Price 7948 Conversion Price 7984
Conversion Privilege Conversion Procedure
Convertible Notes Convertible Notes 2032 Modified
Convertible Senior Due 2011 Convertible Senior Due 2013
Convertible Senior Notes Due 2011 Pricing Terms Convertible Senior Notes Due 2013 Pricing Terms
Corporate Compliance Program Cannot Guarantee Potentially Applicable Federal Corporate Compliance Risk Mitigation Programs Cannot Guarantee Potentially
Corporate Responsibility Compliance Committee Corporate Seal
Corporation Cost Sales
Counterparty Credit Risks Counterparty Representations
Counting Votes Country
County Erie Abbott Laboratories Inc County Erie Abbott Laboratories Inc Schenectady Oswego
County Oswego County Oswego Abbott Laboratories Inc
County Schenectady Abbott Laboratories Inc Covenant Comply Securities Laws Purchase
Covenants Covenants Agrees Dealer
Credit Agreement Credit Event Merger
Credit Support Document Credit Support Provider
Crediting Accounts Credits Account
Cross Reference Table Current Economic Conditions Magnify Certain Risks Affect Business
Current Levels Market Volatility Unprecedented Adverse Capital Credit Current Products Development Cannot Sold Not Gain Maintain
Current Products Development Cannot Sold Not Maintain Regulatory Current Rule Allows Small Minority Frustrate Shareholder Majority
Currently Face Competition Biosimilar Products Expect Increasing Future Cusip 031162ap5
Cusip Numbers Custodian Means Receiver Trustee Assignee Liquidator Similar Official
Czech Republic Daiichi Sankyo Limited
Daily Accrual Value Daily Effective Rate
Daily Federal Funds Rate Daily Notional Amount
Daily Rebate Value Daily Share Purchase Amount
Daily Share Purchase Value Data Privacy Consent Following Provision Replaces Agreement
Data Privacy Consent Following Provision Replaces Award Agreement David Baltimore
Dealer Death Disability Retirement Benefits Long-term Incentive Equity Awards
Death Disability Retirement Benefits Lti Equity Awards Defaulted Interest
Deferred Income Taxes Deficit Daily Value
Definitions Delaware Corporation
Delivered Shares Delivery Requirements
Denmark Dennis Fenton
Dennis Fenton Executive Vice President Operations Elects Retire Denosumab
Denosumab Announced Submitted Information Requested Fda Prolia Complete Denosumab Developments
Denosumab Oncology Denosumab Osteoporosis
Denosumab Phase Bone Metastases Clinical Trials Denosumab Program Formerly Identified Amg 162
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment Compensatory
Dependent Parties Significant Portion Bulk Supply Formulation Fill Deposit Change Control Purchase Price
Depreciation Derivative Class Actions
Derivative Financial Instruments Derivative Instruments
Determination Final Determining Award Amounts
Difference Between Stockholder Record Street Name Holder Difficulties Disruptions Delays Manufacturing Failure Comply Regulations Limit
Difficulties Disruptions Delays Manufacturing Limit Supply Products Product Director Compensation
Directors Directors Continuing Office Until 2007 Annual Meeting Stockholders
Directors Continuing Office Until 2008 Annual Meeting Stockholders Directors Continuing Office Until 2009 Annual Meeting Stockholders
Disability Waiver Discharge Indenture
Discharge Liability Securities Disclaimer
Disclosure Dispute Resolution
Distribution Distribution Alternate Payee Qdro Freezing Participant Accounts
Distribution Benefits Following Separation Service Distributions
Distributions General Dividends
Documents Incorporated Reference Dompé Biotec Spa
Donald Rice Dulanermin Rhapo2l Trail
Duration Amendment Termination Duties Trustee
Early 2008 Early Termination Date
Earnings Per Share Earnings Per Share Guidance 2005
Earnings Per Share Guidance 2006 Earnings Per Share Guidance Ending 2006
Earnings Per Share Guidance Ending 2007 Earnings Per Share Guidance Ending 2008
Earnings Per Share Guidance Ending 2009 Earnings Per Share Guidance Ending 2010
Economic Environment Economic Political Developments
Effect Change Control Purchase Notice Effect Supplemental Indentures
Effective 2005 Effective 2006
Eip Approved Awards Gmip Award Chief Financial Officer Eip Awards
Eip Awards Performance Goals Eip Awards Performance Goals Target
Elden Amgen Inc Election Directors
Elements Executive Officer Compensation Program Elements Named Executive Officer Compensation Programs
Eligibility Eligibility Awards
Eligibility Disqualification Eligibility Participation
Eligible Contract Participant Line Business Eliminating Classification Board Directors
Elimination Supermajority Voting Employee Contributions
Employee Retirement Income Security Act 1974 Erisa Litigation Employee Stock Purchase Plan
Employees Other Agents Employment Agreements Other Arrangements
Enbrel Enbrel Etanercept
Enbrel Reimbursement Majority Prescription Claims Paid Through Private Enbrel Supply Agreement
Enforceable Trustee Each Capacities Hereunder Agent Custodian Other Entry Material Definitive Agreement
Epogen Epogen Epoetin Alfa
Epogen Facetimes New Roman Size1 Epoetin Alfa Epogen Revenue Recognition
Epresentations Arranties Ovenants Equipment Connectivity
Equity Award Committee Equity Awards
Equity Awards Policy Equity Incentive Plan
Erisa Class Action Erisa Litigation
Erm Ermination Esa Developments
Esa Products Continue Review Receive Scrutiny Regulatory Authorities Esa Regulatory Reimbursement Developments
Esas Estimated Payments Bonanni
Estimated Payments Bradway Estimated Payments Morrow
Estimated Payments Perlmutter Estimated Payments Sharer
Estimated Potential Payments Estimates
Euro Rate Advances Events Default
Every Provision Indenture Way Relates Trustee Subject Paragraphs Ex-
Exact Name Registrant Specified Charter Except Continuance Event Default
Excess Daily Value Exchange Control Notification
Execution Execution Authentication
Execution Copy Executive Committee
Executive Compensation Objectives Executive Compensation Website
Executive Incentive Plan Executive Nonqualified Retirement Plan
Executive Officers Registrant Executive Performance Criteria
Executive Summary Executives Exercise Wide Discretion Over Corporate Resources Political
Exercise Options Exhibits Schedules
Expect Face Increasing Competition Biosimilar Products Impact Profitability Experience Difficulties Delays Unexpected Costs Not Achieve Anticipated
Experience Difficulties Delays Unexpected Costs Not Achieve Maintain Extension Maturity Date
Extraordinary Transaction Face Uncertainties Related Recently Announced Wyeth Pfizer Merger
Facilities Factors Affect Amgen
Fail Prevail Present Future Intellectual Property Litigation Business Fair Value Disclosures Employee Stock Options
Fair Value Measurement Fair Value Measurement Financial Instruments
Fair Values Financial Instruments Federal
Federal Antitrust Litigation Federal Derivative Litigation
Federal Derivative Litigation Rosenblum Sharer Federal Income Tax Consequences
Federal Securities Litigation Amgen Inc Final Settlement Date
Final Settlement Value Final Stock Settlement Shares
Financial Accounting Standards Board Codification Financial Accounting Standards Board Fasb Codification
Financial Information Financial Statements Exhibits
Financing Financing Arrangements
Floating Rate Notes 2017 2037 Floating Rate Senior Notes Due 2008
Following Directors Served Boards Rated Corporate Library Following Provisions Apply Resident Quebec
Forced Undertake Cost Savings Restructuring Initiatives Future Foreign Currency Sensitive Instruments
Form 10-k Form 10-q
Form 8-k Form Award Notice
Form Dating Form Face Security
Former Name Address Changed Since Last Report Formulate Fill Finish Substantially Products Puerto Rico Manufacturing
Formulation Fill Finish Forward Looking Statement
Forward Looking Statements Forward-looking Statement
Forward-looking Statement Amgen Forward-looking Statements
Fractional Shares Frank Biondi
Frank Herringer FranÇois Carbonnel
Frederick Gluck Fresenius
Fresenius Medical Care North America Fresenius Medical Care North America Inc
Furthermore Aware Data Not Used Direct-marketing Purposes Addition General
General Medicine General Provisions Supplemental Retirement Plan Nonqualified Deferred Compensation
Geographic Area Financial Information Geographic Information
George Morrow Gilbert Omenn
Glaxosmithkline Glaxosmithkline Agreement
Glaxosmithkline Plc Gluck
Goodwill Governance Nominating Committee
Governing Law Governing Law Agreement Shall Governed Construed Accordance State
Government Regulation Grant Nonqualified Stock Option
Granting Awards Granting Options
Gross Proceeds 5000000000 Group Participants
Grown Rapidly Fail Adequately Manage Growth Business Adversely Guarantee Merrill Lynch Inc
Guaranty Guidance
Guidance Update Guidelines Membership Board Directors
Guidelines Recommendations Published Various Organizations Reduce Products Harris Amgen Inc Ramos
Healthcare Conference Healthcare Reform
Held 2007 Held 2008
Held 2009 Hereby Explicitly Unambiguously Consent Collection Processing Transfer Electronic
High Overall Governance Risk Assessment Highly Compensated Employee Definition
Hong Kong Householding Proxy Materials
Human Genome Sciences Hgs Litigation Human Genome Sciences Hgs Litigations
Human Genome Sciences Litigation Human Genome Sciences Litigations
Human Resources Ilypsa Inc
Imitation Iability Nsurance Ndemnification Immediate Release
Immediately After Giving Effect Such Transaction Default Shall Immunex Corporation
Immunex Governmental Investigations Important Notice Regarding Availability Proxy Materials 2008 Shareholder
Important Notice Regarding Availability Proxy Materials 2009 Shareholder Income Taxes
Incorporation Reference Incorporation Reference Trust Indenture Act
Increased Commitments Additional Banks Increased Percent 104
Increases Decreases Total Direct Compensation Indemnification
Indemnified Party Independent Registered Public Accountants
Independent Registered Public Accounting Firm Index
Index Exhibits Index Financial Statement Schedules
Index Financial Statements India
Individual Rights Trustee Inflammation
Inflammatory Disease Information Reporting Requirements
Initial Price Initial Purchase Event
Insider Trading Policy Inspector Election
Insurance Intangible Assets
Intangible Assets Goodwill Integrated Facilities Management Services Agreement
Intellectual Property Positions Challenged Invalidated Circumvented Expire Fail Interest Costs
Interest Expense Net Interest Other Income Expense Net
Interest Other Income Net Interest Payments
Interest Rate Sensitive Financial Instruments Interest Rights Preserved
Internal Revenue Code International Trade
International Trade Itc Introduction
Introduction Plan History Introduction Plan Purpose
Inventories Inventories Produced Preparation Product Launches
Investing Investment Options Srp Nonqualified Deferred Compensation Plan 401
Investments Participants Accounts Investor Information
Invoicing Ireland
Israel Bio-engineering Project Litigation Israel Bio-engineering Project Litigation Ibep
Italy Iuoe Local Astrazenaca Plc
Jerry Choate Johnson
Joint Ventures Business Relationships Jpmorgan Chase Bank
Judith Pelham Kennedy Institute Amgen Inc Wyeth
Kepivance Kepivance Palifermin
Kevin Sharer Key Analytic Tools
Key Developments Kirin Brewery Limited
Kirin Holdings Limited Larson Sharer
Leave Absence Legal Holidays
Legal Proceedings Legal Settlement
Legal Settlements Legend Additional Transfer Exchange Requirements
Leonard Schaeffer Liability
License Agreement Arbitration Licensing Developments
Limitation Awards Shares Available Limitation Suits
List Exhibits Included Form 10-k Available Payment Cost Litigation Developments
Loans Loans Executive Officers
Loans Officers Others Long-term Debt
Long-term Incentive Equity Awards Long-term Incentive Plan Awards
Long-term Incentives Lti Equity Awards
Maintained 455 475 Maintenance Office Agency
Major Customers Majority Vote Proposal Received High Levels Support Last
Managements Report Internal Control Over Financial Reporting Managements Role Establishing Compensation
Manufacture Formulate Fill Finish Substantially Products Puerto Rico Manufacturing
Manufacturing Developments Manufacturing Difficulties Disruptions Delays Limit Supply Products Product
Manufacturing Distribution Raw Materials Manufacturing Initiatives
Manufacturing Raw Materials Market Price Sensitive Instruments
Marketed Products Face Substantial Competition Marketed Products Face Substantial Competition Other Companies Discover
Marketing Distribution Marketing Enbrel Dependent Part Pfizer Formerly Wyeth
Marketing Enbrel Dependent Part Wyeth Master Services Agreement
Matching Gift Program Maturity Date
Maximum Awards Medicare Evidence Development Coverage Advisory Committee Medcac
Medicare Other Forms Public Health Insurance Medium Long-term Notes
Memorandum Merge Transfer Assets
Metabolic Disorders Method Exercise Following Provision Replaces
Mexico Miscellaneous
Miscellaneous Provisions Modifications Advance Notice Provisions
Modified Convertible Notes Motesanib
Motesanib Diphosphate Motesanib Diphosphate Formerly Known Amg 706
Multi-vendor Environment Cooperation Parties Multibranch Party
Multiple Myeloma Solid Tumors Multiple Originals
Multiple Solid Tumors Myeloma Name Person Filing Proxy Statement Other Registrant
Negative Covenants Nephrology
Netherlands Netting Payments
Neulasta Neulasta Neupogen
Neulasta Pegfilgrastim Neupogen
Neupogen Filgrastim New Plan Benefits
Nominal Settlement Date Nominees Election Three-year Term Expiring 2009 Annual Meeting
Nominees Election Three-year Term Expiring 2010 Annual Meeting Non-cash Compensation
Non-gaap Financial Measures Non-us
Nonqualified Deferred Compensation Nonqualified Deferred Compensation Plan
Nonqualified Retirement Plan Not Able Develop Commercial Products
Not Realize Anticipated Benefits Merger Abgenix Inc Not Specify Shares Voted
Notation Exchange Securities Notes
Notes 2014 Notes 2037
Notes 2038 Notes 2039
Notes Reconciliation Gaap Earnings Adjusted Excluding Stock Option Notice Adjustment
Notice Annual Meeting Stockholders Held 2006 Notice Certain Transactions
Notice Defaults Notices
Notices Address Agency Notifications
Notwithstanding Provisions Event Conversion Rate Exceed 139024 Shares Nplate Romiplostim
Nplate Size1 Romiplostim Off-balance Sheet Arrangements
Officer Stock Ownership Guidelines Officers
Offices Omecamtiv Mecarbil Amg 423
Oncology Oncology Emerging Markets
Onfidentiality Operating
Operating Expense Analysis Adjusted Basis Option Exercises Stock Vested
Ortho Biotech Antitrust Litigation Ortho Biotech Arbitration
Ortho Biotech Litigation Ortho Biotech Products Antitrust Litigation
Ortho Biotech Spillover Arbitration Osteoporosis
Other Other Benefits
Other Benefits Agreements Other Charges
Other Collaborations Other Compensation
Other Developments Other Events
Other Facilities Other Information Reporting Requirements
Other Long-term Notes Other Matters
Other Net Other Pipeline Developments
Other Postmarketing Commitments Other Primarily Certain Restructuring Costs 2007
Other Programs Other Regulatory Developments
Other Relationships Other Remedies
Other Revenues Other Safety Activities
Other Securities Corporation Other Settings
Other Stock Awards Outstanding Securities Determinations Holders Action
Overview Overview Compensation Philosophy
Ownership Securities Shall Proved Register Maintained Registrar Page
Panitumumab Part
Part Financial Information Part I-financial Information
Participating Subsidiaries Affiliates Amgen Inc Participation
Party Contracts Patents Competition
Patents Trademarks Paul Reason
Paying Agent Hold Money Securities Trust Payment Awards
Payment Interest Payment Securities
Payments Early Termination Peer Group Companies
Peer Group Market Information Peer Market Information
People State Illinois Abbott Laboratories Inc Per Share Increased 090
Percent Excluding Impact Performance Award Program
Performance Graph Performance Period Goals 2009 Program
Performance Program Awards Performance Program-performance Units Granted
Performance Unit Agreement Performance Units
Performance Units 2005 -2007 2006 -2008 Periods Performance Units 2006-2008 Period
Performance Units 2007 2009 Period Performance Units 2008-2010 Period
Performance-based Compensation Perquisites
Person Persons Deemed Owners
Pfizer Inc Pfizer Inc Formerly Wyeth
Pharmaceutical Industry Average Wholesale Price Litigation Mdl 1456 Pharmaceuticals Division
Phase Pills Entrench Current Management
Plan Supplemental Retirement Please Sign Date Return Promptly Using Enclosed Envelope
Poison Pill Management Was Still Protected Low Trigger Poland
Policies Grants Long-term Incentive Equity Awards Policies Grants Lti Equity Awards
Portugal Positive Final Settlement Value
Postmarketing Safety Activities Postmenopausal Osteoporosis Trials
Potential Future Labeling Changes Risk Management Activities Including Power Attorney
Preamble Preclinical
Preferred Stock Preoperative Epirubicin Paclitaxel Aranesp Prepare Study
President Chief Financial Officer Pricing
Principal Interest Principles Consolidation
Priorities Private Health Insurance
Process Agent Product Candidates
Product Development Efforts Not Result Commercial Products Product Information Full Prescribing Please Refer Amgen Web
Product Information Full Prescribing Please Refer Amgen Website Product Pipeline Highlights
Product Pipeline Update Product Returns
Product Sales Product Sales Incentives Returns
Product Sales Performance Progress Begins Step
Projects Prolia Denosumab Prevention Treatment Pmo Bone Loss Patients
Prolia Prevention Treatment Pmo Bone Loss Patients Undergoing Prolia Received Positive Opinion Chmp
Property Plant Equipment Property Plant Equipment Net
Proposal Submitted Gloria Eddie Proposal Topic Won Impressive Support Following Companies Based
Proposals Nominations Pursuant Bylaws Proposals Pursuant Rule 14a-8
Proposed Amendment Restated Certificate Incorporation Proposed Bundled Payment System
Proposed Bylaw Declassification Amendment Proposed Charter Declassification Amendment
Prospectus Protection Confidential Information
Provide Stock Provided
Provisions Clauses Below Shall Apply Only Global Securities Provisions Shall Survive Termination Agreement Completion Transactions Contemplated
Provisions Together Others North Dakota Act Give Shareowners Proxy Card Revocation
Proxy Holder Stockholder Owned Shares Common Stock Close Purchase Agreement
Purchase Price Purchase Price Adjustment
Purpose Qui Tam Actions
Raised 480-495 Raised 490-505
Range 400 430 Range 413 423 Per Share
Range 430 450 Range 505 525
Ratification Selection Independent Registered Public Accountants Raw Materials
Raw Materials Medical Devices Receive Proxy Card
Receive Proxy Card Notice Received Legal Proxy Bank Broker Other Nominee Please
Recent Accounting Pronouncements Recent Labeling Changes Risk Management Activities Required Regulatory
Recent Labeling Updates Esas Potential Future Changes Recommendations Recent Levels Market Volatility Been Unprecedented Adverse Capital
Recent Proposed Accounting Pronouncements Recitals
Reclassifications Reconciliation Adjusted Research Development Expense Guidance Gaap Ending
Record Holder Common Stock Close Business 2008 Then Recourse Against Others
Redeem Vote Poison Pill Refusal Withdrawal Consent Affect Ability Participate Plan Information
Registered Public Accountants Registrable Securities
Registrants Business Operations Registrants Telephone Number Including Area Code
Registrar Paying Agent Conversion Registration Procedures Indemnification
Registration Rights Registration Rights Agreement
Regulation Disclosure Reimbursement
Reimbursement Outside United States Reimbursement Principal Products
Reimbursement System Related Party Transactions
Rely Single Third-party Suppliers Some Raw Materials Medical Rely Single-source Third-party Suppliers Certain Raw Materials Medical
Remainder Page Intentionally Left Blank Signature Follows Reorganization Special Distributions
Repayment Repayment Event
Replacement Securities Replacement Trustee
Report Include Amgens Definition Sustainability Well Company-wide Review Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Internal Control Reports Trustee Holders
Representations Warranties Representations Warranties Buyer
Reproductive Health Drugs Advisory Committee Rhdac Requests
Required Consents Required Defend Lawsuits Pay Damages Product Liability Claims
Required Perform Additional Clinical Trials Change Labeling Products Research Development
Research Development Costs Reserved
Resignation Richard Nanula Resigning Trustee
Resolved Shareholders Request Board Redeem Current Future Poison Responsibilities
Restated Certificate Incorporation Amgen Inc Restricted Stock Unit Agreement
Restricted Stock Unit Agreements Restricted Stock Units
Restructuring Restructuring Activities
Results 2007 Odac Panel Meeting Esas Likely Result Results Operations Financial Condition
Retiree Medical Savings Account High Deductible Health Plan Retirement Benefits Savings Deferred Compensation Plans
Retirement Dennis Fenton Retirement Savings Plan Nonqualified Deferred Compensation Supplemental
Retirement Savings Plan Supplemental Revenue Eps Guidance Raised
Revenues Revenues Fluctuate Fluctuation Cause Financial Results Below Expectations
Revenues Fluctuate Operating Results Subject Fluctuations Cause Financial Revenues Grew Percent
Review Chief Executive Officer Revocation Effect Consents Waivers Actions
Rhapo2l Trail Richard Nanula
Rights Holders Receive Payment Rights Issued Respect Common Stock Conversion
Rights Trustee Robert Swanson Tap Pharmaceutical Products Inc
Robert Swanston Tap Pharmaceutical Products Inc Roche Matters
Roger Perlmutter Romiplostim Formerly Known Amg 531
Roth Elective Deferrals Rule 10b5-1 Purchase Plan
Rules Construction Rules Trustee Paying Agent Conversion Registrar
Russia Sale Purchase
Sales Depend Coverage Reimbursement Third-party Payers Sample
Savings Deferred Compensation Plans Schedule
Sclerostin Amg 785 Scope Work
Sec Other Reports Secretary
Securities Class Actions Securities Law Notification Stock Awards Offered Hereunder Considered
Securities Owned Corporation Securities Purchased Part
Securities Registered Pursuant Act Common Stock 00001 Par Securities Shall Executed Behalf Officer Signature Manual Facsimile
Securities Shall Issued Only Registered Form Without Coupons Securities Trading Markets
Security Ownership Certain Beneficial Owners Security Ownership Directors Executive Officers Certain Beneficial Owners
Security Ratings Above Not Recommendation Buy Sell Hold Securityholder Lists
Select Acceleration Provisions Option Not Fully Vested Date Selected Operating Expenses
Selected Succeed Fenton Selection Enrollment Eligibility
Seller Disclosure Schedule Selling General Administrative
Selling General Administrative Costs Senior Notes Due 2017
Senior Notes Due 2018 Senior Notes Due 2019
Senior Notes Due 2037 Senior Notes Due 2038
Senior Notes Due 2039 Sensipar Abbreviated New Drug Application Anda Litigation
Sensipar Cinacalcet Sensipar Cinacalcet Hcl
Separability Clause Series Junior Participating Preferred Stock
Series Preferred Stock Service Levels Customer Satisfaction
Settlement Date Settlement Price
Seventh Amendment Change Control Severance Plan Severability
Severance Plans Employment Agreements Shall Conclusive Evidence Only Such Security Been Duly
Share Based Payments Share Delivery Conditions
Share Ownership Guidelines Shareholders Agreement Kirin-amgen Inc
Shareowners Reimbursed Expenses Proxy Contests Extent They Successful Shares Outstanding Quorum
Shares Stock Shares Subject Plan
Shares Voted Shelf Registration Statement
Shelf Registration Statements Other Facilities Shelf Registrations Other Facilities
Short-term Assets Liabilities Short-term Payout
Signature Signature Page Follows
Signature Page Underwriting Agreement Signature Pages Follow
Signatures Significant Changes Federal State Foreign Tax Laws Regulations
Simultaneous Adjustments Sixth Amendment Change Control Severance Plan
Size Share Pool Slovakia
Software Intellectual Property Rights Solicitation Proxies
Spain Spanish Translation
Special Top-heavy Provisions Specified Entities
Staggered Settlement State
State Alabama Abbott Laboratories Inc State Alaska Abbott Laboratories Inc
State Arizona Abbott Laboratories Inc State Arizona Etc Abbott Laboratories Inc
State Attorney General Amp Awp Investigations State Attorney General Investigations
State Derivative Litigation State Derivative Litigation Birch Sharer
State Derivative Litigation Larson Sharer State Illinois Abbott Laboratories Inc
State Iowa Abbott Laboratories Inc State Kansas Rel Steve Amgen Inc Immunex Corporation
State Mississippi Abbott Laboratories Inc State Wisconsin Amgen Inc
Statement William Steiner Statements Required Certificate Opinion
Stock Option Expense Stock Option Grants
Stock Options Stock Options Restricted Units
Stock Ownership Guidelines Stock Payments Restricted Units
Stock Price Volatile Stock Price Volatile Adversely Affect Investment
Stock Repurchase Program Stock Repurchase Programs
Stock Settlement Deficiency Stock Settlement Deficiency Amount
Stock Settlement Excess Stock Settlement Excess Amount
Stock Subject 1999 Plan Stockholder Approval Requirement
Stockholder Proposal Stockholder Proposal Corporate Political Contributions
Stockholder Proposals Stockholder Proposals Nominations
Stockholder Rights Agreement Stockholder Supporting Statements
Stockholders Equity Submitting Proxy Over Internet Telephone
Subsequent Event Subsequent Events
Successive Adjustments Successor Corporation
Successor Trustee Successor Trustee Merger
Successors Summary Compensation Table
Summary Significant Accounting Policies Supply Agreement
Supporting Statement Supportive Cancer Care
Survivor Benefits Table Contents
Takeda Takeda Pharmaceutical Limited
Tally Sheets Tally Sheets Impact Elements Compensation Other
Target Annual Cash Compensation Target Awards
Tax Considerations Tax Deductibility 162 Internal Revenue Code
Tax Deductibility Considerations Tax Rate Guidance Ending 2010
Tax Representations Taxes Conversion
Temporary Securities Temporary Suspension Trading Registrants Employee Benefit Plans
Term Term Sheet Relates Only Securities Described Below Supplements
Termination Termination Amendment Modification
Termination Employment Termination Material Definitive Agreement
Terms Conditions Terms Discretionary Options
Terms Non-discretionary Options Awarded Non-employee Directors Terms Restricted Stock Units Rsus
Terms Stock Bonuses Purchases Restricted Teva Amgen 603 Patent Litigation
Teva Amgen G-csf Patent Litigation Teva Patent 7449603 603 Litigation
Thank Vote Third- Party Payors Class Actions
Third-party Payers Litigation Third-party Payors Litigation
Title Definitions Total Compensation
Total Direct Compensation Trading
Transaction Transaction Term
Transactions Related Persons Transfer Conversion
Transformation Transkaryotic Therapies Aventis Litigation
Transkaryotic Therapies Tkt Aventis Litigation Trc Capital Corporation
Treat Study Treatment-induced Bone Loss Trials
Trial Trust
Trust Fund Plan Investments Trust Indenture Act Controls
Trustee Trustee Not Relieved Liability Own Negligent Action Failure
Trustee Proofs Claim Trustee Sign Supplemental Indentures
Trustees Adjustment Disclaimer Trustees Disclaimer
Tularik Inc Understand Employer Affiliate Hold Certain Personal Information Including
Undertaking Costs Underwriter
United Kingdom United States
Urge Shareholders Support Resolution Valuation Accounts
Valuation Acquired Intangible Assets Vance Coffman
Vectibix Vectibix Developments
Vectibix Facetimes New Roman Size1 Panitumumab Vectibix Panitumumab
Vesting Participants Accounts Violation Conflict
Vitro Vivo
Volatility Current Financial Markets General Economic Slowdown Magnify Volatility Current Financial Markets Magnify Certain Risks Affect
Voluntary Conversion Continuation Advances Vote
Voting Person Voting Shares
Voting Shares Writing Changing Vote Waiver Jury Trial
Waiver Past Defaults Waiver Stay Extension Usury Laws
Warren General Hospital Amgen Welfare Benefits
What Voting Whereas
Whereas Published Animal Welfare Care Policy Prominently Posted Withdrawals While Employed
Withholding Taxes Adjustments Conversion Rate Without Consent Holders
Write-off Acquired In-process Research Development Wwwamgencom
Wyeth Xpansion Greement
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki